This is a prospective, open-label therapeutic interventional investigation designed to interrogate the efficacy and safety of individualized matched therapies in patients with pancreatic cancer at high risk of disease recurrence post-surgery.
Age ≥18 years.
Pathologically confirmed pancreatic cancer (excluding neuroendocrine histology).
Pancreatic tumor is surgically removed and
patient has received multimodal therapy (neoadjuvant, sandwich or adjuvant chemotherapy ± radiation) or
CA 19-9 non-producers, unless high-risk pathological features present.
Receiving concomitant investigational agent(s) for pancreatic ductal adenocarcinoma (PDAC).
Radiographic evidence of metastatic disease.
Inability to ingest study drugs by mouth.